We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Cipher Pharmaceuticals Inc (CPH) NPV

Sell:8.90 CAD Buy:9.27 CAD Change: 0.1 CAD (1.14%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
Sell:8.90 CAD
Buy:9.27 CAD
Change: 0.1 CAD (1.14%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
Sell:8.90 CAD
Buy:9.27 CAD
Change: 0.1 CAD (1.14%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

Contact details

5750 Explorer Drive,, Suite 404
L4W 0A9
+1 (905) 6025840

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
216.60 million CAD
Shares in issue:
24.11 million
Toronto Stock Exchange
Canadian dollars

Key personnel

  • Craig Mull
    Chairman of the Board, Interim Chief Executive Officer
  • Bryan Jacobs
    Chief Financial Officer, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.